SEC filing · 8-K

Lexeo Therapeutics, Inc.: Material agreement

Lexeo Therapeutics agreed to acquire Mantle Therapeutics to expand its Friedreich ataxia pipeline.

Filed September 22, 2026

Positive for the company

What happened

Lexeo entered into a merger agreement to acquire Mantle Therapeutics for an upfront purchase price of $5,300,000 in cash and $3,000,000 in common stock.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Lexeo Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.